February 16, 2026
Novonesis CSO Claus Fuglsang on leading the biosolutions revolution through its $12B merger, a powerful R&D engine, and customer-centricity.
February 9, 2026
Cereno Scientific's CEO on repurposing an old drug for PAH, detailing positive Phase 2a data, a multi-layered IP strategy, and a large retail investor base.
January 12, 2026
Transgene's CEO discusses next-gen cancer vaccines, individualized therapies, and their recent €105M fundraising to advance their platforms.
January 6, 2026
Biotech veteran Pascal Touchon on the cell therapy evolution, from Kymriah to in vivo CAR-T, and JTO's data-driven investment strategy.
![Sten R. Sörensen, Cereno Scientific 🇸🇪 | Drug Repurposing, Retail Investors | E52 [Sponsored] thumbnail](https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_episode/38602414/38602414-1770668818564-0e3602876c1a2.jpg)
